This is indeed an exciting time for our vaccine franchise. I'll now move on to update on ARCT-810. This is our mRNA therapeutic candidate for OTC deficiency. This investigational medicine is designed to address the deficient OTC enzyme in the liver and thereby restore urea cycle activity and to prevent metabolic crises that cause neurological damage. ARCT-810 could potentially liberalize the strict dietary protein restrictions that OTC patients face today and improve quality of life for those living with this condition. ARCT-810 utilizes Arcturus' proprietary LUNAR delivery technology, an important attribute of our technology is that the lipids administered are rapidly degraded, which we expect lead to a favorable safety profile. ARCT-810 is being evaluated in two ongoing clinical studies in patients, a Phase 1b study in adults and a multi-dose Phase 2 study in adolescents and adults.